Compare Booz Allen Hamilton Holding Corporation (BAH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Sana Biotechnology Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.5 (market cap $9.45B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 8.4× Sana Biotechnology Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BAH | SANA | |
|---|---|---|
Market Cap | $9.45B | $1.13B |
Sector | Industrials | Health |
52-Week High | $111.63 | $5.92 |
52-Week Low | $59.71 | $2.68 |
Enterprise Value | $13.07B | $1.05B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $78.4, up 0.64% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 68.11% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights its focus on AI and cybersecurity, with a consensus analyst price target of $84.67 suggesting upside potential. Cash flow from operations improved to $1.01 billion in 2025.
The outlook is supported by national security demand and margin expansion, but risks include civil revenue weakness and high leverage. Valuation appears reasonable with a P/E of 12.33. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock offers a dividend yield from recent payouts.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
